Safety of KN057 Prophylaxis in Patients With Haemophilia A or B | stella

Learn About Find trials matched to me

About Learn Find trials matched to me →

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Privacy ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety of KN057 Prophylaxis in Patients With Haemophilia A or B | stella

Back to Hemophilia A or B trials

Recruiting

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(1 site)

China

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality

Key details

Phase

Large-scale testing

Sponsor

Suzhou Alphamab Co., Ltd.

Enrollment target

~70 participants

Started

March 2026

Primary completion

December 2027

Age range

12 Years – 65 Years

Sex

View full record on ClinicalTrials.gov

Male only

Last updated on clinicaltrials.gov in April 2026.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

Yanrong Dong, Master

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Enrollment status is pulled from ClinicalTrials.gov and may not reflect real-time availability. If a trial appears full when you reach out, the team will let you know.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.